Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.69M | -21.91M | -19.05M | -31.75M | -60.45M |
| Total Depreciation and Amortization | 1.10M | 1.23M | 1.33M | 1.39M | 1.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.53M | 10.13M | 10.46M | 12.48M | 16.12M |
| Change in Net Operating Assets | -22.41M | 6.56M | -3.38M | -11.73M | -7.28M |
| Cash from Operations | -24.47M | -3.99M | -10.65M | -29.61M | -50.41M |
| Capital Expenditure | -90.00K | 0.00 | -29.00K | -127.00K | -44.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.47M | -16.67M | 7.23M | 14.84M | 9.99M |
| Cash from Investing | 3.38M | -16.67M | 7.20M | 14.72M | 9.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -235.00K | -197.00K | -233.00K | -227.00K | -215.00K |
| Issuance of Common Stock | -- | 50.81M | 93.00K | 9.37M | 1.73M |
| Repurchase of Common Stock | -93.00K | -- | -- | -6.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -14.82M | -184.00K | 15.00M | 0.00 |
| Cash from Financing | -328.00K | 35.79M | -324.00K | 24.14M | 1.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.42M | 15.14M | -3.77M | 9.25M | -38.95M |